NEW YORK (GenomeWeb) – Illumina and Bristol-Myers Squibb announced after the close of the market Friday that they will collaborate on developing and commercializing companion diagnostics to support BMS' oncology drug pipeline.

The companies plan to develop a diagnostic version of Illumina's TruSight Oncology 500, an assay being developed to target most of the known biomarkers for cancer drugs, including tumor mutation burden and miscrosatellite instability. The panel will run on Illumina's NextSeq 550Dx.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.